The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York,

Slides:



Advertisements
Similar presentations
Fraud in the Pharmaceutical Industry
Advertisements

The Deficit Reduction Act, Deficit Reduction Act of 2005 In the Deficit Reduction Act of 2005 (DRA) Congress, for the first time, has mandated healthcare.
QUI TAM - QUI WHAT? Perspectives From Experienced Government Counsel,
Why False Claims Matter
Hill Country CMHMR Center FRAUD & ABUSE Training August 2008.
North Carolina False Claims Act (WEBCAST) Presented by: The North Carolina Bar Association Tuesday, November 27, :00PM – 1:30PM.
What Every Physician Needs To Know About Fraud And Abuse Laws (But Is Afraid To Ask) Steven H. Cohen Cohen Law Group an affiliate of the Whistleblower.
© 2009 Cengage Learning. All Rights Reserved. Healthcare Fraud and Abuse.
Food and Drug Law Institute Understanding cGMPs Failure to Comply: What Are the Consequences? Jeffrey Steger Assistant Director, Consumer Protection Branch.
Fraud in the Pharmaceutical Industry
UNIVERSITY OF PENNSYLVANIA Institutional Compliance Strategies at the University of Pennsylvania.
The False Claims Act and Its Impact on Federally Sponsored Research Jeff M. Seo J.D., LL.M. Director of Research Compliance Harvard Medical School.
BlueCare Tennessee and BlueCare, Independent Licensees of BlueCross BlueShield Association How the Deficit Reduction Act of 2005 Impacts BlueCare Tennessee.
1 PsychRights' Medicaid Fraud Initiative Against Psychiatric Drugging of Children & Youth James B. (Jim) Gottstein, Esq. Law Project for Psychiatric Rights.
2011 FRAUD & ABUSE UPDATE John Hellow Hooper, Lundy & Bookman, PC All views expressed in the seminar materials and.
*smith&nephew Getting Management Buy-In Soft Sell Tie compliance to “Core Values” “Corporate Mantra” Competitive differentiation: Sell relationship safety.
False Claims Act & Whistleblower Protection. False Claims Act The False Claims Act (FCA) was established in 1863 by President, Abraham Lincoln, to curb.
False Claims in Construction, Update of NCHRP Study Topic
FCA* for BEGINNERS *NEVADA FALSE CLAIMS ACT NRS et seq. L. TIMOTHY TERRY The Terry Law Firm, Ltd
April 26–28, 2004 Renaissance Orlando Resort at Seaworld Orlando, FL NCMA World Congress 2004 “Maximizing Value to Stakeholders…Contract Management in.
Enforcement in the Pharmaceutical Industry Michael K. Loucks First Assistant U.S. Attorney United States Attorney’s Office District of Massachusetts October.
Chapter 51 Accountants’ Duties and Liability
Regulatory Control of Providers Financial Relationships Civil False Claims The Act.
United States ex rel. Cheryl Eckard v. GlaxoSmithKline Safeguarding cGMP Compliance for Patients and the Public Lesley Ann Skillen, Getnick & Getnick LLP.
MID INVESTIGATIONS Douglas Thoren Criminal Chief Medicaid Investigations Division North Carolina Department of Justice.
Maryland State Bar Association Health Law Section Understanding Medicare Billing Issues: Anti-Markup Rules, Independent Diagnostic Testing Facility Rules,
 Most states have whistleblower protection laws, although some apply only to public- sector employees.  Some whistleblowers are protected under laws.
Fraud, Waste & Abuse DEFICIT REDUCTION ACT OF 2005 Presented by: MARCH Vision Care, 2013.
DIVISION OF HEALTH SCIENCES OFFICE OF INSTITUTIONAL INTEGRITY Protecting Yourself and Your Practice.
THE NEW PARADIGM OF PUBLIC-PRIVATE PARTNERSHIPS: THE NEW YORK MODEL © 2011 Getnick & Getnick LLP November 2011 Getnick & Getnick LLP | Counsellors At Law.
Federal False Claims Act and Qui Tam Actions Law Journal Press Webinar By: Joel M. Androphy, Sarah Frazier & Rachel Grier Berg & Androphy1.
Violations of the False Claims Act and The Importance of a Timely and Proper Response to Whistleblower Allegations Thomas J. Finn Paula Cruz Cedillo.
*All views contained in this presentation reflect the personal views of the presenter only. They do not necessarily reflect the views or position of Mylan.
KEEPING IT LEGAL James A. Calderwood, Attorney Zuckert, Scoutt & Rasenberger, LLP (o)
1 Medicaid Fraud and Abuse Investigations, Prosecutions and Compliance Strategies John T. Bentivoglio Combating Medicaid.
False Claims Act and Whistleblower Protections False Claims Act and Whistleblower Protections Genetic Disease Screening Program Employee Education and.
Recent False Claims Developments Robert J. Sherry K&L Gates May 2009.
Copyright© 2011 WeComply, Inc. All rights reserved. 9/6/2015 Whistleblowing.
© 2010 Cengage Learning. All Rights Reserved. May not be scanned, copied or duplicated, or posted to a publicly accessible website, in whole or in part.
COMPLIANCE PROGRAM. Agenda  Initial Scenarios  Review of General Compliance Information  Review UCP’s Compliance Program  Questions and Discussion.
False Claims Act in Brief Taxpayers Against Fraud.
WHEN THE DEPARTMENT OF JUSTICE KNOCKS DOJ Enforcement Trends: What to Expect and How to Respond Jacqueline Arango Shareholder Akerman Senterfitt.
Sales and Marketing in the Pharmaceutical Industry: At the Vortex of the Perfect Legal Storm Paul E. Kalb, M.D., J.D. Princeton, N.J. - June 7, 2004.
Fraud and Abuse in Dentistry. Definition Fraud is the intentional perversion of truth in order to induce another to part with something of value, or surrender.
1 VIEW ON FRAUD AND ABUSE David E. Matyas Epstein Becker & Green Washington, DC.
September 2015 Medicaid Fraud False Claims Act Sunset Review Legislative Auditor’s Conclusion: The Legislature should reauthorize the Medicaid Fraud False.
KEY ENFORCEMENT ISSUES - The Government's Perspective Kathleen Meriwether Assistant United States Attorney Eastern District of Pennsylvania UNITED STATES.
The Ninth Annual Pharmaceutical Regulatory Compliance Congress and Best Practices Forum Thomas E. Costa Bristol-Myers Squibb Company This presentation.
1 National Pharma Audioconference: Pharmaceutical Drug Pricing and Reporting Issues Overview of Department of Justice Prosecution of Drug Pricing and Reporting.
When Pharmaceutical Marketing Crosses the Line: Best Practices For Investigation and Remediation.
THE SECOND ANNUAL FDA REGULATORY AND COMPLIANCE SYMPOSIUM THOMAS M. GREENE Greene & Hoffman August 25, 2006 LESSONS FROM WHISTLE-BLOWER CASES.
1 United States Commercial Law Seminar Masaryk University April 11-21, 2011 Lecture Six: Internal investigations, Special Committees, and directorduties.
National Medical Device Audioconference: How the Recent Landmark $311 Million Device Settlements Will Change Industry Practices Insights Into Federal Investigations.
Welcome General Compliance Training.  To inform you who to contact to ask questions  To let you know that you are responsible to disclose  To share.
December 2015 Medicaid Fraud False Claims Act Sunset Review Legislative Auditor’s Conclusion: The Legislature should reauthorize the Medicaid Fraud False.
Lessons Learned from Federal Prosecutions Michael K. Loucks First Assistant U.S. Attorney District of Massachusetts.
The Growing Role of HHS-IG/DOJ, & Whistleblowers, In Drug Marketing Policy John F. Kamp August 25, 2005.
Ann Williams Investigator Eastern District of Texas.
Thomas J. Finn Paula Cruz Cedillo
Trends: Two Months & Four Settlements That Have Changed Our World
FRAUD, WASTE, & ABUSE (FWA) 2012
FCA Enforcement: United States Department of Justice
Northern Michigan Regional Entity Region 2
Liability Under CERCLA
COMPLIANCE PROGRAM.
National Medicaid Congress
Brussels, June 6, 2007 Paul E. Kalb, M.D., J.D.
Introduction to Qui Tam Litigation
Mandatory Subcontractor Flow-Downs and Mandatory Disclosures:
PsychRights' Medicaid Fraud Initiative Against Psychiatric Drugging of Children & Youth James B. (Jim) Gottstein, Esq. Law Project for Psychiatric Rights.
Presentation transcript:

The United States False Claims Act Qui Tam Whistleblower Law Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York, NY Phone: (212) | Fax: (212) |

The False Claims Act, 31 U.S.C. Sec ff  Creates a civil cause of action for all types of fraud on the government  Treble damages and penalties of $5,500-$11,000 per violation  Liability may arise from:  Actual knowledge  Reckless disregard  Deliberate ignorance

The False Claims Act Qui Tam Law  Action may be brought by the government or by a private citizen in the name of the government (the qui tam “relator”)  Most relators have private legal representation  Relator is entitled to receive 15-30% of the proceeds (with exceptions) plus attorneys fees and costs  Plus action for employment retaliation

A Short History  Passed by the Lincoln Administration in  The qui tam law is “firmly rooted in the American legal tradition.”  Strengthened by President Reagan in 1986 and President Obama in 2009  The qui tam law is a “public-private partnership.”  29 States and the District of Columbia now have qui tam statutes.

FCA Recoveries  Total: $30.3 billion  $21.0 billion qui tam  Health Care Fraud: $ 21.0 billion  $15.8 billion qui tam  Defense Fraud: $4.9 billion  Other: $4.4 billion

Qui Tam Procedure  Relator files Complaint under seal in federal or state court and serves the Complaint and statement of material facts on the DOJ and/or State AGs  DOJ and/or State AGs and agencies investigate and government decides whether to intervene in the action or decline to do so  Relator may proceed if the government declines  Relator must have legal representation if proceeding without the government

Checks and Balances  Cases are barred if the allegations are substantially the same as those:  on the public record  in an existing filed case  Defendant may recover attorneys fees and costs from relator if case is “frivolous or vexatious” more …

Checks and Balances (cont.)  Relator who “planned and initiated” the violations may receive zero, in the court’s discretion  Relator who is criminally convicted in relation to the violations must receive zero

Relator Awards Awards total $3.4B of $21B recovered 15-25% 18% 25-30% > 15% 0

Potential Collateral Consequences  Criminal prosecution  Corporate Integrity Agreements  Class/shareholder/SEC/private insurer actions  Exclusion from federal programs  Foreign Corrupt Practices Act actions  Cessation of conduct and deterrence

Pharmaceutical CompanyDate SettledPrimary Fraud AllegedWhistleblower/s Criminal Fine Civil SettlementTotal Recovery GlaxoSmithKline7/2/2012Off-label promotion; kickbacks; failing to report safety data; pricing fraud 4 GSK employees, incl. Snr Marketing Manager and Regional VP $1 Billion $2 Billion$3 Billion Pfizer9/2/2009Off-label promotion; kickbacksSeveral Pfizer sales reps $1.3 Billion $1 Billion$2.3 Billion Abbott Laboratories5/7/2012Off-label promotion; kickbacksSeveral Abbott sales reps $800 Million $1.6 Billion Eli Lilly1/15/2009Off-label promotion; kickbacksSeveral Eli Lilly sales reps $615 Million $800 Million$1.415 Billion Merck11/22/2011Off-label promotion $ Million $628.3 Million$950 Million TAP Pharmaceuticals10/3/2001Marketing the spread; kickbacksTAP V-P of Sales and HMO Medical Director $290 Million $585 Million$875 Million GlaxoSmithKline10/26/2010Manufactured and sold adulterated drug products GSK Global Quality Assurance Manager $150 Million $600 Million$750 Million Serono10/17/2005Off-label promotion; kickbacks5 Serono employees (Lab and Sales) $136.9 Million $567 Million$704 Million Merck2/7/2008Concealing Best Price; kickbacksMerck District Sales Manager/Physician $650 Million Allergan Inc.9/1/2010Off-label promotion; kickbacksAllergan Managers and consultant $375 Million $225 Million$600 Million AstraZeneca4/27/2010Off-label promotion; kickbacksAstraZeneca sales rep $520 Million Bristol-Myers Squibb7/28/2007Off-label promotion; marketing the spread Independent Pharmacy and others $515 Million Schering Plough8/29/2006Concealing Best Price; off-label promotion 3 Schering Plough sales reps $180 Million $255 Million$435 Million Warner-Lambert5/13/2004Off-label promotion; kickbacksWarner Lambert Medical Liaison $240 Million $190 Million$430 Million Cephalon9/29/2008Off-label promotion; kickbacks3 Cephalon sales representatives $50 Million $375 Million$425 Million Novartis Pharmaceuticals9/30/2010Off-label promotion; kickbacksFormer sales representatives $185 Million $237.5 Million$422.5 Million Abbott, B. Braun and Roxane Laboratories 12/7/2010Marketing the spreadIndependent pharmacy $421.1 Million Elan7/15/10 & 12/15/10 Off-label promotionPhysician $100 Million $317.5 Million$417.5 Million

Getnick & Getnick LLP | Counsellors At Law Rockefeller Center, 620 Fifth Avenue | New York, NY Phone: (212) | Fax: (212) |